Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches

L. Ereshefsky, S. R. Saklad, M. W. Jann, C. M. Davis, A. Richards, D. R. Seidel

    Research output: Contribution to journalReview articlepeer-review

    62 Scopus citations

    Abstract

    The future of depot neuroleptic therapy is discussed in terms of pharmacokinetic and pharmacodynamic research opportunities. Analytic methods for neuroleptic assays, including chromatographic, radioreceptor, nuclear magnetic resonance, and radioimmunoassay techniques, are briefly reviewed. Elucidation of depot neuroleptic multicompartment kinetics utilizing nonlinear mixed-effects modeling and the usefulness of these data in interpreting plasma levels are discussed. The clinical significance of plasma monitoring of depot fluphenazine, including the development of dosage conversion guidelines, is presented. The relationships between haloperidol and its metabolite reduced haloperidol (RH) are discussed in terms of dosage form and response. Clinical advantages resulting from the availability of more depot neuroleptics are discussed.

    Original languageEnglish (US)
    Pages (from-to)50-59
    Number of pages10
    JournalJournal of Clinical Psychiatry
    Volume45
    Issue number5 II
    StatePublished - Aug 2 1984

    ASJC Scopus subject areas

    • Psychiatry and Mental health

    Fingerprint Dive into the research topics of 'Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches'. Together they form a unique fingerprint.

    Cite this